Abstract
Background: Apigenin (APG), a natural bioactive flavonoid has multiple pharmacological effects. However, its poor aqueous solubility hinders its clinical benefits.
Objective and Methods: The work aimed to develop novel apigenin-loaded niosomes (APG-NIO) with ecological probe sonication techniques. The formulation was statistically optimized by Box-Behnken design (BBD) and the independent variables were selected as Span 80(X1), Poloxamer 188(X2), and Tween 80(X3) at three levels, and the dependent variables were identified as: particle size (Y1), polydispersity index (Y2), and % entrapment efficiency (Y3). The formulation was characterized for various parameters such as vesicle shape, size, PDI, %EE, solubility, in vitro drug release, and antioxidant potential.
Results: The optimized APG-NIO formulation was found to have a spherical shape with homogenous distribution and a low polydispersity index. It has a particle size of 425.77 nm, zeta potential -17.1±0.9 mV, and % EE of 89.63. The aqueous solubility of APG-NIO was found approximately 45 times higher than that of pure APG. The formulation showed a higher drug release rate as compared to pure APG in phosphate buffer pH 7.4 and followed the Higuchi release model with a non-Fickian transport mechanism. The stability was found at 4°C for 3 months. The antioxidant potential of APG-NIO was significantly increased in comparison to the pure drug suspension in the DPPH• assay.
Conclusion: These findings suggest that the probe sonication technique is an alternative, cost-effective, simple, and green method for the development of niosomes, and BBD is a useful optimization tool for identifying the effect of formulation variables.
Keywords: Apigenin, niosomes, probe sonication, box-behnken design, antioxidant, oral delivery.
Graphical Abstract
[http://dx.doi.org/10.1007/s11095-010-0089-7] [PMID: 20306120]
[http://dx.doi.org/10.1080/10942912.2016.1207188]
[http://dx.doi.org/10.1016/j.jff.2018.07.037]
[http://dx.doi.org/10.1016/j.ejps.2016.12.009] [PMID: 27939619]
[http://dx.doi.org/10.1016/j.ejps.2016.09.002] [PMID: 27600819]
[PMID: 17722549]
[http://dx.doi.org/10.1016/j.msec.2016.07.043] [PMID: 27612773]
[http://dx.doi.org/10.1208/s12249-014-0183-y] [PMID: 25182386]
[http://dx.doi.org/10.5101/nbe.v9i3.p242-248]
[http://dx.doi.org/10.31557/apjcb.2017.2.2.27-29]
[http://dx.doi.org/10.1016/j.jddst.2019.01.012]
[http://dx.doi.org/10.1208/s12249-016-0622-z] [PMID: 27604883]
[http://dx.doi.org/10.1016/j.jddst.2020.101763]
[http://dx.doi.org/10.1080/00401706.1960.10489912]
[http://dx.doi.org/10.1016/j.ijbiomac.2014.05.066] [PMID: 24915550]
[http://dx.doi.org/10.1080/02652048.2019.1701114] [PMID: 31810417]
[http://dx.doi.org/10.9734/jpri/2020/v32i130394]
[http://dx.doi.org/10.1016/j.ijpharm.2017.12.047] [PMID: 29294324]
[http://dx.doi.org/10.1016/j.jddst.2019.101356]
[http://dx.doi.org/10.1016/j.cherd.2013.05.032]
[http://dx.doi.org/10.1186/s43094-020-00023-3]
[http://dx.doi.org/10.1208/s12249-012-9805-4] [PMID: 22644706]
[http://dx.doi.org/10.1080/10717544.2017.1399302] [PMID: 29115900]
[http://dx.doi.org/10.1080/10717544.2016.1247928] [PMID: 28165809]
[http://dx.doi.org/10.1016/j.ijpharm.2011.08.018] [PMID: 21871547]